EUVIMEDObjevte EUVIMED
Crossref

Analysis of IL‐10 and IL‐35 in dipeptidyl peptidase‐4 inhibitor‐related bullous pemphigoid

Hiraku Kokubu iD, Toshifumi Takahashi, Miho Kabuto, Hideaki Kouzaki, Noriki Fujimoto

Experimental Dermatology · 2023

DOI: 10.1111/exd.14880 ↗

At a glance

Journal article in Experimental Dermatology, 2023. Written by Hiraku Kokubu and 4 co-authors. Institution: Department of Dermatology, Shiga University of Medical Science, Otsu, Japan. Major MEDLINE topics: Dipeptidyl-Peptidase IV Inhibitors, Pemphigoid, Bullous, Diabetes Mellitus, Type 2. Cited 1 times so far (Crossref); 19 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

The association between immunoregulatory cytokines, such as interleukin (IL)‐10 or IL‐35, and dipeptidyl peptidase‐4 inhibitor (DPP4i)‐related bullous pemphigoid (BP) has not been evaluated. Serum IL‐10 and IL‐35 levels were measured in 39 patients with BP (24 males and 15 females; 6 DPP4i‐related and 33 DPP4i‐unrelated BP patients) and 10 healthy controls. The number of CD26 + cells in the dermis around bulla on sections was counted immunohistochemically for 12 patients (six patients with DPP4i‐related BP and six randomly sampled patients with DPP4i‐unrelated BP). Patients with DPP4i‐related BP had lower levels of serum eosinophils (DPP4i‐related vs. DPP4i‐unrelated BP: 476.1 ± 234.0 vs. 911.3 ± 948.8/μL; p = 0.537) and a higher rate of infiltrating CD26 + cells (32.9 ± 7.1% vs. 15.7 ± 4.4%; p = 0.01). There were no significant differences in serum IL‐10 (6.77 ± 0.24 vs. 6.84 ± 0.20 pg/mL), serum IL‐35 (2.63 ± 0.17 vs. 2.63 ± 0.21 pg/mL), serum anti‐BP180NC16a antibodies (67.31 ± 37.4 vs. 76.18 ± 54.59 U/mL) and Bullous Pemphigoid Disease Area Index before treatment in this study. Serum IL‐10 and IL‐35 levels do not increase in patients with BP and may not be a candidate for a therapeutic target for BP. An increase in CD26 + cells might be associated with DPP4i‐related BP.

Subjects

MeSH terms (MEDLINE)

Dipeptidyl-Peptidase IV InhibitorsPemphigoid, BullousDiabetes Mellitus, Type 2MaleFemaleHumansDipeptidyl Peptidase 4Interleukin-10Hypoglycemic Agents

Author keywords

CD26DPP-4 inhibitorIL-35L-10bullous pemphigoid

Substances

Dipeptidyl-Peptidase IV InhibitorsDipeptidyl Peptidase 4Interleukin-10Hypoglycemic Agents

Authors and institutions

  • Department of Dermatology, Shiga University of Medical Science, Otsu, Japan.
  • Department of Otolaryngology-Head and Neck Surgery, Shiga University of Medical Science, Otsu, Japan.

ORCID profiles: Hiraku Kokubu

Cite

APA

Kokubu, H., Takahashi, T., Kabuto, M., Kouzaki, H., & Fujimoto, N. (2023). Analysis of IL‐10 and IL‐35 in dipeptidyl peptidase‐4 inhibitor‐related bullous pemphigoid. Experimental Dermatology. https://doi.org/10.1111/exd.14880

Vancouver

Kokubu H, Takahashi T, Kabuto M, Kouzaki H, Fujimoto N. Analysis of IL‐10 and IL‐35 in dipeptidyl peptidase‐4 inhibitor‐related bullous pemphigoid. Experimental Dermatology. 2023. doi:10.1111/exd.14880

BibTeX
@article{Kokubu2023,
  author = {Kokubu, Hiraku and Takahashi, Toshifumi and Kabuto, Miho and Kouzaki, Hideaki and Fujimoto, Noriki},
  title = {Analysis of IL‐10 and IL‐35 in dipeptidyl peptidase‐4 inhibitor‐related bullous pemphigoid},
  journal = {Experimental Dermatology},
  year = {2023},
  doi = {10.1111/exd.14880}
}
Start for free →